Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954204 | 0.80 | PTGDR2 (0.54) | PTGDR2RXFP1SLC40A1SLC22A12CYP2C9 | |
| SCHEMBL2449417 | 0.75 | RXFP1 (0.66) | PTGDR2RXFP1SLC40A1SLC22A12CYP2C9 | |
| SCHEMBL17578631 | 0.74 | SLC40A1 (0.58) | PTGDR2RXFP1SLC40A1SLC22A12CYP2C9 | |
| SCHEMBL2444727 | 0.74 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL2444046 | 0.70 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL2444023 | 0.70 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL20627706 | 0.68 | PTGDR2 (0.63) | PTGDR2RXFP1SLC40A1SLC22A12CYP2C9 | |
| SCHEMBL27710758 | 0.68 | HSD11B1 (0.50) | PTGDR2RXFP1 | |
| SCHEMBL2444120 | 0.67 | EPHX2 (0.55) | PTGDR2RXFP1SLC40A1SLC22A12CYP2C9 | |
| SCHEMBL2444220 | 0.67 | PTGDR2 (1.00) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796280-B2 | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors | Merck Serono, S.A. (CH) | 2014-08-05 | — | — | US | disclosed |
| US-8796280-B2 | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors | Merck Serono, S.A. (CH) | 2014-08-05 | — | — | US | disclosed |
| US-8796280-B2 | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors | Merck Serono, S.A. (CH) | 2014-08-05 | — | — | US | disclosed |
| EP-1871374-B1 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | MERCK SERONO SA (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-1871374-B1 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | MERCK SERONO SA (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2009-02-26 | — | — | US | disclosed |
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2009-02-26 | — | — | US | disclosed |
| EP-1871374-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | Laboratoires Serono SA (CH) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111560-A2 | 2,3 SUBSTITUTED PYRAZINE SULFONAMIDES AS INHIBITORS OF CRTH2 | LABORATOIRES SERONO S.A. (CH) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054447-A1 | 2,3 Substituted Pyrazine Sulfonamides as Inhibitors of CRTH2 | HRH2, HRH1, HRH4 | PTGDR2 84/4885RXFP1 1817/4885SLC40A1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.